Kasim Kutay
Born (1965-05-13) May 13, 1965
Alexandria, Egypt
CitizenshipUnited Kingdom
EducationBSc. and MSc. - London School of Economics
EmployerMorgan Stanley (1989–2007)

Sun Group (2007–2009) Moelis & Company (2009–2016)

Novo Holdings A/S (2016–present)
Title
Board member of
SpouseMaha Arakji Kutay
Children3

Kasim Kutay (born 13 May 1965) is a British fund manager who is the CEO of Danish Novo Holdings A/S, an investment fund that manages investments and assets for the Novo Nordisk Foundation. He holds British citizenship and resides in Denmark.

Kasim Kutay was a investment banker, focusing on the healthcare sector.[1] Kasim Kutay assumed the role of CEO at Novo Holdings A/S on September 1, 2016, following the departure of Eivind Kolding.[2][3][4] Kasim Kutay joined Novo Holdings A/S after more than two decades working within investment banking.

Early life and education

Kasim Kutay is a citizen of the United Kingdom. He was born in Alexandria, Egypt on 13 May 1965 to a Turkish father and Syrian mother.[3]

The family moved to Lebanon until the Lebanese Civil War broke out in 1975 where the family relocated to London, United Kingdom.[3]

Prior to studying at LSE (London School of Economics and Political Science), Kasim Kutay went to the American Community School in London.[3]

He studied at the London School of Economics and Political Science, where he attained his Master of Science in Economics in 1987. Kasim Kutay holds a BSc in Economics and an MSc in Politics of the World Economy, both from the LSE (London School of Economics and Political Science).

Career

Kasim Kutay began his career, with his first job as a graduate trainee at Morgan Stanley in 1989.[3] Kasim Kutay spent 18 years at Morgan Stanley advising mainly healthcare companies.[5]

He rose to the post of chairman of its European Healthcare Group.[4] After 18 years at Morgan Stanley, Kasim Kutay worked at a private US investment firm, Sun Group,[3] prior to joining Moelis & Company in 2009.

He joined Moelis & Company in 2009, where he worked for seven years, serving as Co-head of Europe and member of its Management Committee until he joined Novo Holdings A/S in 2016.[6][1]

Novo Holdings A/S

Kasim Kutay was appointed CEO of Novo Holdings A/S in June 2016, succeeding Eivind Kolding.

Kasim Kutay was very familiar to Novo Holdings A/S before assuming the role of CEO, having previously advised the company over many years on both disposals and acquisitions. He has also advised several other Danish healthcare companies including William Demant and Lundbeck.[2]

Novo Holdings A/S manages approximately DKK 710 billion Danish Kroners[2][3] (approximately $106bn)[3] worth of assets.

Philanthropy and public positions

Kasim Kutay has written on and advocated for the need for greater investment and policy changes to tackle the pandemic of antimicrobial resistance (A Plan to Avert a ‘Superbug’ Pandemic).[7]

In 2018, Novo Holdings A/S launched REPAIR, a $165 million fund solely dedicated to investing in companies researching new antibiotics (REPAIR Impact Fund · Novo Holdings launches US$165m impact fund to combat antimicrobial resistance.[8]

Kasim Kutay is an advocate for the greater adoption of biotech solutions in industry and agriculture to assist in the green transition[9][10] and the need for a quicker bioindustrial approval process in Europe to match US timelines. Novo Holdings is an active investor in bioindustrial companies, with a portfolio of eighteen companies in the sector.[10] [11]

Kasim Kutay has been involved in the launch of Best For You, a new model of care for adolescent mental health, based at the Chelsea and Westminster Hospital (Best For You -video- CW+).[12]

Kasim Kutay has written on the need for capital markets to evolve to be more conducive to companies seeking to pursue a “stakeholder” model by restraining certain types of hostile mergers and acquisitions (Kasim Kutay (telegraph.co.uk).[13]

Kasim Kutay is a member of the board of directors at Novozymes,[14][15] Novo Nordisk A/S,[16] Evotec SE[17] and a former board member of Convatec up until July 3 - 2018.[18][19]

Kasim Kutay is also a charity board member of the Chelsea and Westminster NHS Foundation Trustt.[3]

Personal life

Kasim Kutay currently resides in Denmark and is married to architect Maha Arakji Kutay.[3] The couple have three children.[20]

References

  1. 1 2 "Archived copy" (PDF). Archived from the original (PDF) on 2017-03-06. Retrieved 2017-03-05.{{cite web}}: CS1 maint: archived copy as title (link)
  2. 1 2 3 "Investment firm Novo names Moelis's Kutay as new chief executive". Bloomberg.com. 21 June 2016. Retrieved 12 January 2022.
  3. 1 2 3 4 5 6 7 8 9 10 Meddings, Sabah (2018-11-04). "Interview: biotech boss Kasim Kutay is investing billions — according to Jante". The Sunday Times. ISSN 0956-1382. Retrieved 2018-12-10.
  4. 1 2 "After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle". Fiercebiotech.com. 22 June 2016. Retrieved 5 March 2017.
  5. ↑ "Kasim Kutay: Executive Profile & Biography - Bloomberg". Bloomberg News. Retrieved 5 March 2017.
  6. ↑ "Novo A/S appoints new CEO". PharmaTimes. June 21, 2016.
  7. ↑ Kutay, David A. Ricks and Kasim (8 July 2020). "Opinion | A Plan to Avert a 'Superbug' Pandemic". Wsj.com. Retrieved 12 January 2022.
  8. ↑ "Novo Holdings launches USD 165m impact fund to combat antimicrobial resistance". Repair-impact-fund.com. 28 February 2018. Retrieved 12 January 2022.
  9. ↑ Novo Holdings YouTube Channel: A story about how biology can be harnessed to drive the green transition https://www.youtube.com/watch?v=jATd_I_a83g
  10. 1 2 MedWatch: Novo Holdings sets sights on more acquisitions in hot bioindustry sector https://medwatch.com/News/Pharma___Biotech/article13276777.ece
  11. ↑ "Biosolutions: A clear path to fighting climate change". 23 May 2022.
  12. ↑ "Best For You". Cwplus.org.uk. 15 December 2020. Retrieved 12 January 2022.
  13. ↑ "Kasim Kutay". The Daily Telegraph. June 2020. Retrieved 12 January 2022.
  14. ↑ "Board of Directors in Novozymes". Novozymes.com. Retrieved 5 March 2017.
  15. ↑ "The Novo Team". Novo.dk. Retrieved 5 March 2017.
  16. ↑ "Kasim Kutay". Archived from the original on 2017-04-09. Retrieved 2017-04-08.
  17. ↑ "Evotec SE virtual Annual General Meeting 2020 approves all proposed agenda items". Evotec.com.
  18. ↑ "03 July 2018 - Board Changes | Convatec Group". Convatecgroup.com. Retrieved 2018-11-29.
  19. ↑ "Proposed directorate changes" (PDF). Convatecgroup.com. Retrieved 12 January 2022.
  20. ↑ Novo-Holdings press release 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.